Drug Profile
Research programme: interleukin-1 receptor-associated kinase-4 inhibitors - Aurigene Oncology
Alternative Names: IRAK4 inhibitors - Aurigene OncologyLatest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Cancer in India (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in India
- 24 Jun 2014 Preclinical trials in Cancer in India (unspecified route)